A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
CONFIDENCE
A Parallel-group Treatment, Phase 2, Double-blind, Three-arm Study to Assess Efficacy and Safety of Finerenone Plus Empagliflozin Compared With Either Finerenone or Empagliflozin Alone in Participants With Chronic Kidney Disease and Type 2 Diabetes.
3 other identifiers
interventional
1,664
14 countries
173
Brief Summary
Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD. Empagliflozin lowers blood sugar levels by increasing the excretion of glucose from the blood into the urine. In this study, the researchers want to learn how well the combination of finerenone and empagliflozin helps to slow down the worsening of the participants' kidney function compared to either treatment alone. For this, the level of protein in the urine will be measured. The investigators also want to know how safe the combination is compared to either treatment alone. Depending on the treatment group, the participants will either take the combination of finerenone and empagliflozin, or finerenone together with a placebo, or empagliflozin together with a placebo, once a day as tablets by mouth. A placebo looks like a treatment but does not have any medicine in it. Importantly, the participants will also continue to take their other current medicine for CKD and T2D. The participants will be in the study for up to 7.5 months and will take the study treatments for 6 months. During the study, participants will visit the study site 7 times. The study team will:
- collect blood and urine samples
- check the participants' vital signs
- do a physical examination including height and weight
- check the participants' heart health by using an electrocardiogram (ECG)
- monitor the participants' blood pressure
- ask the participants questions about how they are feeling and what adverse events they may be having An adverse event is any problem that happens during the trial. Doctors keep track of all events that happen in trials, even if they do not think the events might be related to the study treatments.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2 type-2-diabetes-mellitus
Started Jun 2022
Longer than P75 for phase_2 type-2-diabetes-mellitus
173 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 4, 2022
CompletedFirst Posted
Study publicly available on registry
February 24, 2022
CompletedStudy Start
First participant enrolled
June 23, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 14, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
March 17, 2025
CompletedResults Posted
Study results publicly available
July 13, 2026
CompletedJuly 13, 2026
June 1, 2026
2.7 years
February 4, 2022
March 6, 2026
June 16, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Empagliflozin Alone
Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) at Day 180 relative to baseline, estimated using a mixed model for repeated measures. The treatment effect is expressed as the ratio of LS means for the combination therapy group compared with empagliflozin alone. A ratio below 1 indicates a reduction in UACR relative to baseline. UACR is a marker of albuminuria and a predictor of long-term renal and cardiovascular outcomes in participants with chronic kidney disease and type 2 diabetes.
Baseline and Day 180
Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Finerenone Alone
Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) at Day 180 relative to baseline in the combination therapy group compared with finerenone alone, estimated using a mixed model for repeated measures. A ratio below 1 indicates a reduction in UACR relative to baseline. UACR is a measurement of albuminuria and a predictor of long-term renal and cardiovascular outcomes in participants with type 2 diabetes.
Baseline and Day 180
Secondary Outcomes (20)
Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 210 Relative to Day 180
Up to 210 days
Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at 30 Days After End of Treatment Relative to Baseline
Baseline to Day 210 (30 days after End of Treatment)
Number of Participants by Relative Change in UACR Category at Day 180 (>30%, >40%, >50%)
At Day 180
Change From Baseline in eGFR at 30 Days
At Day 30
Number of Participants With an eGFR Decline Greater Than 30% at 30 Days From Baseline
Up to 30 days
- +15 more secondary outcomes
Study Arms (3)
Finerenone and Empagliflozin
EXPERIMENTALParticipants will take Finerenone (10 or 20 mg once daily \[OD\]) and Empagliflozin (10 mg OD) for up to 180 days.
Finerenone and Empagliflozin placebo
EXPERIMENTALParticipants will take Finerenone (10 or 20 mg OD) and matching placebo to Empagliflozin (OD) for up to 180 days.
Empagliflozin and Finerenone placebo
EXPERIMENTALParticipants will take Empagliflozin (10 mg OD) and matching placebo to Finerenone (OD). for up to 180 days.
Interventions
oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: \<60 mL/min/1.73 m2
oral administration, once daily
Matching placebo to empagliflozin oral administration, once daily
oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: ≥60 mL/min/1.73 m2
Matching Placebo to Finerenone oral administration once daily
Eligibility Criteria
You may qualify if:
- Participant with a clinical diagnosis of chronic kidney disease (CKD) and the following:
- In Part A: eGFR 40-90 ml/min/1.73m\^2 (with no more than 20% having an eGFR \>75 ml/min/1.73m\^2) using Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula at screening visit and at least one historical value of eGFR \<60 mL/min/1.73 m\^2 within 3 months or have a registered diagnosis of CKD.
- In Part B: eGFR 30-90 ml/min/1.73m\^2 (with no more than 20% having an eGFR \>75 ml/min/1.73m\^2) using CKD-EPI formula at screening visit and at least one historical value of eGFR \<60 mL/min/1.73 m\^2 within 3 months or have a registered diagnostic of CKD.
- ≤UACR \<5000 mg/g at screening visit (mean value from 3 morning void samples) and documentation of albuminuria/proteinuria (quantitative or semi-quantitative measurement) in the participant's medical records at least 3 months prior to screening
- Participant with type 2 diabetes (T2D) as defined by the American Diabetes Association (ADA 2021), with glycated hemoglobin (HbA1c) at screening \<11%.
- Participant treated with the clinically maximum tolerated dose, as per investigator judgment, of angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), but not both, for more than 1 month at screening visit.
You may not qualify if:
- Participants with type 1 diabetes (T1D).
- Participant with hepatic insufficiency classified as Child-Pugh C.
- Participant with blood pressure at Day 1 visit (Visit 2) higher than 160 systolic blood pressure (SBP) or 100 diastolic blood pressure (DBP) or SBP lower than 90 mmHg.
- Participant currently treated with a sodium/glucose cotransporter-2 inhibitor (SGLT2i) or SGLT-1/2i or who received a SGLT2i or SGLT-1/2i which cannot be discontinued at least 8 weeks prior to the screening visit and during study intervention treatment.
- Participant treated with another mineralocorticoid receptor antagonist (MRA) (e.g., eplerenone, esaxerenone, spironolactone, canrenone), a renin inhibitor, potassium supplements, a potassium sparing diuretic (e.g., amiloride, triamterene), a potassium binder agent, or angiotensin receptor-neprilysin inhibitor (ARNI) which cannot be discontinued at least 8 weeks prior to the screening visit and during study intervention treatment.
- Participants currently treated or who were treated with Finerenone (Kerendia©) within 8 weeks prior to the screening visit.
- Participant with serum/plasma potassium (K+) above 4.8 mmol/L at screening visit (central laboratory value).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Bayerlead
Study Sites (173)
Southwest Kidney Institute, PLC - Suprise
Surprise, Arizona, 85374, United States
Academic Medical Research Institute
Los Angeles, California, 90022, United States
Dignity Health Northridge Hospital Medical Center - Nephrology
Northridge, California, 91325, United States
Olive View - UCLA Medical Center
Sylmar, California, 91342-1437, United States
Touro University California - Metabolic Research Center
Vallejo, California, 94592, United States
Florida Kidney Physicians - Delray Beach Nephrology
Delray Beach, Florida, 33445, United States
West Orange Endocrinology & Clinical Research
Ocoee, Florida, 34761, United States
Innovative Research Institute
Port Charlotte, Florida, 33952, United States
Metabolic Research Institute, Inc.
West Palm Beach, Florida, 33401, United States
Grady Memorial Hospital - Endocrinology
Atlanta, Georgia, 30303, United States
Southeast Kidney Associates - East Point
East Point, Georgia, 30344, United States
Velocity Clinical Research - Savannah
Savannah, Georgia, 31406, United States
Nola Care Clinical Research
Metairie, Louisiana, 70006, United States
Omega Clinical Research - Metairie
Metairie, Louisiana, 70006, United States
South Shore Nephrology
Plymouth, Massachusetts, 02360, United States
Lake Michigan Nephrology
Saint Joseph, Michigan, 49085, United States
Oakland Medical Research
Troy, Michigan, 48085, United States
Clinical Research Consultants, a JCCT Company
Kansas City, Missouri, 64111, United States
Kansas City VA Medical Center - Endocrinology
Kansas City, Missouri, 64128, United States
Center for Advanced Medicine - Diabetes Center
St Louis, Missouri, 63110, United States
St. Louis Heart and Vascular, PC - Christian Hospital Office
St Louis, Missouri, 63136, United States
Somnos Clinical Research
Lincoln, Nebraska, 68510, United States
Healor Primary Care / CCT Research
Las Vegas, Nevada, 89102, United States
CCT Research - Santa Rosa Medical Centers of Nevada
Las Vegas, Nevada, 89119, United States
Circuit Clinical/Crystal Run
Middletown, New York, 10941, United States
Randolph Health Internal Medicine in Asheboro
Asheboro, North Carolina, 27203, United States
UNC Hospitals Outpatient Center at Eastowne - Nephrology
Chapel Hill, North Carolina, 27514, United States
Eastern Nephrology Associates - Greenville West
Greenville, North Carolina, 27834, United States
Blue Sky, MD/ Lamond Family Medicine
Hendersonville, North Carolina, 28792, United States
Eastern Nephrology Associates - Kinston
Kinston, North Carolina, 28504, United States
Velocity Clinical Research - Blue Ash
Cincinnati, Ohio, 45242, United States
Dunes Clinical Research LLC
Dakota Dunes, South Dakota, 57049, United States
DarSalud Care / LifeDOC Research
Memphis, Tennessee, 38119, United States
The University of Tennessee Health Science Center - Medical Center Clinic - Nephrology
Memphis, Tennessee, 38163, United States
Office of Osvaldo A. Brusco, MD
Corpus Christi, Texas, 78414, United States
Thyroid, Endocrinology, and Diabetes - Dallas
Dallas, Texas, 75208, United States
DaVita Clinical Research- El Paso
El Paso, Texas, 79925, United States
Global Kidney Center
Houston, Texas, 77008, United States
Victorium Clinical Research
Houston, Texas, 77024-2593, United States
North Texas Kidney Disease Associates Lewisville
Lewisville, Texas, 75057, United States
Biopharma Informatic - McAllen, TX
McAllen, Texas, 78503, United States
Clinical Advancement Center, PLLC
San Antonio, Texas, 78212, United States
UT Health San Antonio - Medical Arts & Research Center - Endocrinology
San Antonio, Texas, 78229, United States
Olympus Family Medicine
Salt Lake City, Utah, 84117, United States
Salem VA Medical Center - Endocrinology
Salem, Virginia, 24153, United States
MultiCare Rockwood Clinic Diabetes & Endocrinology Center
Spokane, Washington, 99202, United States
CHU de Charleroi Hôpital civil
Lodelinsart, Hainaut, 6042, Belgium
Onze-Lieve-Vrouwziekenhuis (OLVZ) - Campus Aalst
Aalst, Oost-vlaanderen, 9300, Belgium
UZ Gent
Ghent, 9000, Belgium
Jan Yperman Ziekenhuis
Ieper, 8900, Belgium
AZ Groeninge Campus Kennedylaan
Kortrijk, 8500, Belgium
UZ Leuven Gasthuisberg
Leuven, 3000, Belgium
AZ Delta
Roeselare, 8800, Belgium
Hamilton Medical Research Group
Hamilton, Ontario, L8M 1K7, Canada
William Osler Health centre, Sakuara Medical
Mississauga, Ontario, L5H4K9, Canada
Bluewater Clinical Research Group
Sarnia, Ontario, N7T 4X3, Canada
Sameh Fikry Professional Corporation
Waterloo, Ontario, N2J 1C4, Canada
Clinical Research Solutions, Inc.
Waterloo, Ontario, N2T 0C1, Canada
GCP Research | Montreal
Montreal, Quebec, H1M 1B1, Canada
Centre Hospitalier de l'Universite de Montreal (CHUM) | Cardiology
Montreal, Quebec, H2X 0A9, Canada
LMC Clinical Research Inc. Montreal
Saint-Laurent, Quebec, H4T 1Z9, Canada
Bispebjerg Hospital - Hjerteafdeling
Copenhagen, Capital Region, 2400, Denmark
Steno Diabetes Center Copenhagen | Herlev - Clinical and Translational Research Department
Herlev, Capital Region, 2730, Denmark
Region Midtjylland | Regionshospitalet Godstrup - Nephrology Department
Herning, Central Jutland, 7400, Denmark
Hospital of South West Jutland | Department of Endocrinology Research
Esbjerg, Region Syddanmark, 6700, Denmark
Center Hospitalier Michallon - Grenoble
La Tronche (Grenoble Area), Auvergne-Rhône-Alpes, 38043, France
Hôpital Edouard Herriot - Lyon Cedex
Lyon, Auvergne-Rhône-Alpes, 69003, France
CHU Dijon - Hopital Francois Miterrand
Dijon, Bourgogne-Franche-Comté, 21000, France
Hopital Carémeau - Nîmes
Nîmes, Occitanie, 30029, France
Many Locations
Many Locations, France
Hôpital Saint Joseph
Paris, Île-de-France Region, 75014, France
Diabetes Zentrum Wandsbek
Hamburg, Free and Hanseatic City of Hamburg, 22041, Germany
ClinPhenomics GmbH&Co. KG
Frankfurt am Main, Hesse, 60596, Germany
Diabetologische Schwerpunkt Praxis Dortmund
Dortmund, North Rhine-Westphalia, 44137, Germany
Zentrum für Diabetologie und Ernährungsmedizin
Ludwigshafen am Rhein, Rhineland-Palatinate, 67059, Germany
Cardiologicum Pirna / Dresden-Seidnitz
Pirna, Saxony, 1796, Germany
Charité Campus Benjamin Franklin (CBF)
Berlin, State of Berlin, 12203, Germany
Friedrich-Schiller-Uni. Jena
Jena, Thuringia, 7747, Germany
King George Hospital
Visakhapatnam, Andhra Pradesh, 530002, India
Mavani Dialysis & Kidney Center
Ahmedabad, Gujarat, 380052, India
Vedanta Kidney Care
Vadodara, Gujarat, 390007, India
K.L.E.S. Dr. Prabhakar Kore Hospital & Medical Research Centre
Belagavi, Karnataka, 590010, India
Vinaya Hospital and Research Centre (A Unit of KIMS)
Mangalore, Karnataka, 575003, India
Manipal Hospital
Mysore, Karnataka, 570015, India
Government Medical College
Kozhikode, Kerala, 673008, India
Seth Gordhandas Sunderdas Medical College (GSMC) - King Edward Memorial (KEM) Hospital
Mumbai, Maharashtra, 400012, India
Asian Kidney Hospital and Medical Centre
Nagpur, Maharashtra, 440010, India
Grant Medical Foundation - Ruby Hall Clinic (RHC)
Pune, Maharashtra, 411001, India
All India Institute of Medical Sciences
Bhubaneswar, National Capital Territory of Delhi, 751019, India
Indraprastha Apollo Hospital
New Delhi, National Capital Territory of Delhi, 110076, India
Sawami Man Singh (SMS) Medical College & Attached Hospitals
Jaipur, Rajasthan, 302017, India
Eternal Heart Care Centre (EHCC) and Research Institute
Jaipur, Rajasthan, 302020, India
Government Kilpauk Medical College Hospital
Chennai, Tamil Nadu, 600010, India
Nizam's Institute of Medical Sciences (NIMS)
Hyderabad, Telangana, 500082, India
Krishna Institute Of Medical Science
Secunderabad, Telangana, 500003, India
Osmania General Hospital
Telangana, Telangana, 500012, India
G.S.V.M. Medical College
Kanpur, Uttar Pradesh, 208002, India
Institute of Post-Graduate Medical Education and Research
Kolkata, West Bengal, 700020, India
Dr. Bantwal's Clinic
Bengaluru, 560076, India
Bangalore Medical College & Research Institute
Bengaluru, India
Sriram Chandra Bhanj Medical College & Hospital
Cuttack, India
Government Medical College and Hospital (GMCH) Nagpur
Nagpur, 440009, India
Max Super Speciality Hospital (MSSH) - Saket
New Delhi, 110017, India
Lifepoint Multispecialty Hospital
Pune, 411057, India
HaEmek Medical Center | Internal Medicine C Department - Research Unit
Afula, 1834111, Israel
Barzilai Medical Center | Department of Nephrology and Hypertension
Ashkelon, 7830604, Israel
Clalit Health | Soroka Medical Center - Internal Medicine Department
Beersheba, 8410101, Israel
Edith Wolfson Medical Center | Internal Medicine Department
Holon, 5822012, Israel
Hadassah University Medical Center (HUMC)
Jerusalem, 911200, Israel
Health Corporation of Galilee Medical Center
Nahariya, 2210001, Israel
Health Corporation of the Ziv Medical Center (R.A.)
Safed, 1311001, Israel
Casa Sollievo della Sofferenza - Endocrinologia
San Giovanni Rotondo, Apulia, 71013, Italy
Azienda Ospedaliero Universitaria Parma - SC Nefrologia
Parma, Emilia-Romagna, 43126, Italy
ASL N 4 SSR Liguria_Ospedale di Chiavari - Diabetologia e Malattie Metaboliche
Chiavari, Liguria, 16043, Italy
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII - Malattie Endocrine e Diabetologia
Bergamo, Lombardy, 24127, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Endocrinologia
Milan, Lombardy, 20122, Italy
Ospedale San Raffaele s.r.l. - Medicina Generale Indirizzo Diabetologico ed Endocrino-Metabolico
Milan, Lombardy, 20132, Italy
Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo_Ospedale S. Paolo - Gestione integrata della malattia Diabetica
Milan, Lombardy, 20142, Italy
Azienda Socio Sanitaria Territoriale Rhodense
Rho, Lombardy, 20017, Italy
Azienda Ospedaliero-Universitaria San Luigi Gonzaga - Malattie Metaboliche Diabetologia
Orbassano, Piedmont, 10043, Italy
Azienda Socio Sanitaria Locale N 2 Della Gallura - Diabetologia
Olbia, Sardinia, 07026, Italy
Azienda Ospedaliero Universitaria Pisana_Cisanello - Malattie Metaboliche e Diabetologia
Pisa, Tuscany, 56124, Italy
Università degli Studi "G. D'Annunzio" di Chieti - Endocrinologia
Chieti, 66100, Italy
Many Locations
Many Locations, Italy
Saiseikai Matsuyama Hospital
Matsuyama, Ehime, 791-8026, Japan
Fukui-ken Saiseikai Hospital
Fukui-shi, Fukui, 918-8503, Japan
Fukuoka University Chikushi Hospital
Chikushino-shi, Fukuoka, 818-8502, Japan
Social Medical Corporation the Chiyukai foundation Fukuoka Wajiro Hospital
Fukuoka, Fukuoka, 811-0213, Japan
Kokura Memorial Hospital
Kitakyushu, Fukuoka, 802-8555, Japan
Hirohata Naika Clinic
Kitakyushu, Fukuoka, 807-0857, Japan
Jiyugaoka Yamada Internal Medicine Clinic
Obihiro, Hokkaido, 080-0848, Japan
Naka Kinen Clinic
Naka, Ibaraki, 311-0113, Japan
Public Central Hospital of Matto Ishikawa | Clinical Trial Management Office
Hakusan, Ishikawa-ken, 924-8588, Japan
Medical Corporation Taifukukai, Osaka Nishiumeda Clinic
Osaka, Osaka, 530-0001, Japan
Osaka General Medical Center
Osaka, Osaka, 558-8558, Japan
Many Locations
Many Locations, Japan
Gelre Ziekenhuizen
Apeldoorn, Gelderland, 7334 DZ, Netherlands
Onze Lieve Vrouwe Gasthuis
Amsterdam, North Holland, 1091 AC, Netherlands
Albert Schweitzer Ziekenhuis | Dordwijk - Cardiology Department
Dordrecht, South Holland, 3318 AT, Netherlands
Meander Medisch Centrum
Amersfoort, Utrecht, 3818 TZ, Netherlands
Soon Chun Hyang University Cheonan Hospital
Cheonan, Chungcheongnam-do, 31151, South Korea
Yonsei University Wonju Christian Hospital
Wŏnju, Gang''Weondo, 26426, South Korea
Hanyang University Guri Hospital
Guri-si, Gyeonggi-do, 471-701, South Korea
Hallym University Sacred Heart Hospital
Anyang-si, Gyeonggido, 14068, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggido, 13620, South Korea
The Catholic University of Korea, Incheon St.Mary's Hospital
Incheon, Incheon Gwang''Yeogsi, 21431, South Korea
Severance Hospital, Yonsei University Health System
Seoul, Seoul Teugbyeolsi, 03722, South Korea
Asan Medical Center | Ophthalmology
Seoul, Seoul Teugbyeolsi, 05505, South Korea
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, 3080, South Korea
Ansan Hospital | Nephrology
Gyeonggi-do, 425-707, South Korea
Kyung Hee University Hospital at Gangdong
Seoul, 5278, South Korea
Hallym University Kangnam Sacred Heart Hospital
Seoul, 7442, South Korea
Complexo Hospitalario Universitario A Coruna | Endocrinologia y Nutricion
A Coruña, A Coruña, 15006, Spain
Area Sanitaria De Ferrol | Medicina Interna
Ferrol, A Coruña, 15405, Spain
Hospital Universitari Vall D Hebron | Nefrologia
Barcelona, Barcelona, 08035, Spain
Hospital Quironsalud Barcelona | Internal Medicine Department
Barcelona, Barcelona, 8023, Spain
Hospital Universitario Virgen De Las Nieves | Medicina Interna
Granada, Granada, 18014, Spain
Hospital Universitario Principe De Asturias | Nefrologia
Alcalá de Henares, Madrid, 28805, Spain
Hospital Universitario Fundacion Jimenez Diaz | Nephrology and Hypertension Department
Madrid, Madrid, 28040, Spain
Hospital Universitario Puerta De Hierro De Majadahonda | Nefrologia
Majadahonda, Madrid, 28222, Spain
Hospital Universitario Virgen De La Victoria | Endocrinologia y Nutricion
Málaga, Málaga, 20910, Spain
Hospital Nisa Sevilla Aljarafe | Endocrinologia y Nutricion
Castilleja de la Cuesta, Sevilla, 41950, Spain
Hospital Clinico Universitario De Valencia | Cardiologia
Valencia, Valencia, 46010, Spain
Hospital Universitario Dr Peset Aleixandre | Nefrologia
Valencia, Valencia, 46017, Spain
Many Locations
Many Locations, Spain
Changhua Christian Hospital
Changhua, Changhua, 50006, Taiwan
Chang Gung Memorial Hospital Kaohsiung
Kaohsiung City, Kaohsiung, 833, Taiwan
Far Eastern Memorial Hospital | Nephrology Department
New Taipei City, New Taipei, 220, Taiwan
Taipei Medical University - Shuang Ho Hospital
New Taipei City, New Taipei, 23561, Taiwan
Taichung Veterans General Hospital
Taichung, Taichung, 40705, Taiwan
Taipei Veterans General Hospital
Taipei, Taipei, 11217, Taiwan
Many Locations
Many Locations, Taiwan
China Medical University Hospital
Taichung, 404327, Taiwan
Related Publications (10)
Agarwal R, Correa-Rotter R, Navaneethan SD, Heerspink HJL, Weir MR, McGill JB, Mottl AK, Nangaku M, Rosenstock J, Rossing P, Vaduganathan M, Scott C, Li L, Brinker M, Kovesdy CP, Green JB, Mann JFE. Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure. Hypertension. 2026 Jun 5. doi: 10.1161/HYPERTENSIONAHA.126.27036. Online ahead of print.
PMID: 42244376DERIVEDAgarwal R, Correa-Rotter R, Navaneethan SD, Fukami K, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Nangaku M, Rosenstock J, Rossing P, Vaduganathan M, Scott C, Li L, Aldworth C, Green JB, Weir MR. Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone. J Am Soc Nephrol. 2026 Mar 29. doi: 10.1681/ASN.0000001071. Online ahead of print.
PMID: 41905767DERIVEDAgarwal R, Green JB, Heerspink HJL, McGill JB, Mottl A, Nangaku M, Rosenstock J, Rossing P, Vaduganathan M, Solis-Herrera C, Scott C, Li L, Brinker M, Aldworth C, Mann JFE. Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial. J Am Coll Cardiol. 2026 Feb 24;87(7):772-784. doi: 10.1016/j.jacc.2025.10.049. Epub 2025 Nov 7.
PMID: 41493296DERIVEDMottl A, Scott C, Green JB, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rosenstock J, Rossing P, Li L, Li N, Vaduganathan M, Agarwal R; CONFIDENCE Trial Investigators. Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial. J Am Soc Nephrol. 2026 Apr 1;37(4):764-776. doi: 10.1681/ASN.0000000928. Epub 2025 Nov 6.
PMID: 41196655DERIVEDAgarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl A, Osonoi T, Pal A, Rossing P, Rosenstock J, Vaduganathan M, Li L, Li N, Scott C, Manjrekar P, Yamashita S, Nangaku M. Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE. Clin J Am Soc Nephrol. 2026 Jan 1;21(1):72-82. doi: 10.2215/CJN.0000000865. Epub 2025 Sep 18.
PMID: 40965042DERIVEDVaduganathan M, Green JB, Heerspink HJL, Kim SG, Mann JFE, McGill JB, Mottl A, Nangaku M, Rosenstock J, Rossing P, Li L, Li N, Rohwedder K, Scott C, Agarwal R. Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial. Nephrol Dial Transplant. 2025 Dec 23;41(1):161-170. doi: 10.1093/ndt/gfaf160.
PMID: 40886054DERIVEDAgarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE Investigators. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025 Aug 7;393(6):533-543. doi: 10.1056/NEJMoa2410659. Epub 2025 Jun 5.
PMID: 40470996DERIVEDAgarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE investigators. COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics. Nephrol Dial Transplant. 2025 Aug 1;40(8):1559-1569. doi: 10.1093/ndt/gfaf022.
PMID: 39916475DERIVEDRossing P. Experimental Designs for Multicomponent Interventions in Kidney and Cardiometabolic Diseases. J Am Soc Nephrol. 2024 Oct 1;35(10):1438-1441. doi: 10.1681/ASN.0000000000000449. Epub 2024 Jul 5. No abstract available.
PMID: 39078403DERIVEDZachariah T, Radhakrishnan J. Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease. Clin J Am Soc Nephrol. 2024 Nov 1;19(11):1499-1512. doi: 10.2215/CJN.0000000000000540. Epub 2024 Jul 22.
PMID: 39037799DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Limitations and Caveats
The trial used a surrogate end point, and we did not follow the participants long enough to adequately measure differences among groups in cardiovascular outcomes or clinical kidney disease progression.
Results Point of Contact
- Title
- Therapeutic Area Head
- Organization
- Bayer
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 4, 2022
First Posted
February 24, 2022
Study Start
June 23, 2022
Primary Completion
March 14, 2025
Study Completion
March 17, 2025
Last Updated
July 13, 2026
Results First Posted
July 13, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.